---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-015672"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:15:06.447705+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress

## Summary
- Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.
- Cash, equivalents and short-term investments $157.7M as of Sept 30, 2021.
- Initiated STRIDE Phase 2b trial for REN001 in PMM; completed LC-FAOD Phase 1b enrollment.
- Appointed Ashley Hall as Chief Development Officer; received US patent notice of allowance for REN001 into 2041.
- Expects Phase 1b results for McArdle disease Q1 2022 and LC-FAOD Q2 2022.

## SEC filing metadata
- accession: 0001558370-21-015672
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000155837021015672/0001558370-21-015672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000155837021015672/rphm-20211111x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-015672
- JSON: https://secwatch.observer/filing/0001558370-21-015672.json
- Plain text: https://secwatch.observer/filing/0001558370-21-015672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.